Analysis of C. difficile infection–related outcomes in European participants in the bezlotoxumab MODIFY I and II trials

Volume: 39, Issue: 10, Pages: 1933 - 1939
Published: Jun 6, 2020
Abstract
The MODIFY I/II trials demonstrated that bezlotoxumab, a human monoclonal antibody against Clostridioides difficile toxin B, given during antibiotic treatment for Clostridioides difficile infection (CDI) significantly reduced C. difficile recurrence (rCDI) in adults at high risk for rCDI. Efficacy of CDI-directed intervention may depend on ribotype regional epidemiology, and patient characteristics. This post hoc analysis assessed the efficacy...
Paper Details
Title
Analysis of C. difficile infection–related outcomes in European participants in the bezlotoxumab MODIFY I and II trials
Published Date
Jun 6, 2020
Volume
39
Issue
10
Pages
1933 - 1939
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.